ACDM News Item

FDA Guidance for Industry

Date: April 25, 2023

The FDA has issued a final guidance to provide information on risk-based approaches to monitoring the conduct of clinical investigations of human drug and biological products, medical devices, and combination products.

Find out more.

Explore More News

Regulatory Considerations DMEG Update – August 2026

Please read the following update from the Regulatory Considerations DMEG: July and . . .

Get to know ACDM Board Member: Santosh Karthikeyan Viswanathan

We caught up with one of ACDM’s new Board Members, Santosh Karthikeyan Viswanathan, to . . .

Guidance on Decentralized Clinical Trials to be Reviewed by the ACDM RC DMEG

Health Canada (HC) continues to publish new guidelines to support their modernization of . . .

Regulatory Considerations DMEG to Review Health Canada’s Draft Guidance

Thank you to the Regulatory Considerations DMEG for sharing this update. Health Canada . . .

Recent update from the regulatory landscape in clinical data management

Thank you to the Regulatory Considerations DMEG for sharing this update. On July 15 the . . .

Regulatory Considerations DMEG Update – June 2026

Please read the following update from the Regulatory Considerations DMEG: Regulators have . . .

FDA Announces New Initiative for Real-Time Clinical Trials

The U.S. Food and Drug Administration (FDA) has announced a new initiative to support the . . .

Get to know ACDM Board Member Jennifer Duff

We caught up with one of ACDM’s new Board Members, Jennifer Duff, to learn more about her. . . .

Recent News in Regulatory Landscape

The ACDM Regulatory Considerations DMEG have kindly put together a short news piece . . .

Real-Time Clinical Data Flow: Why the FDA’s New Pilot Validates the Data Flow Modernization Agenda

Tamer Chowdhury, on behalf of ACDM Technology DMEG. On April 28, FDA Commissioner Dr. . . .

Bridging the Behaviour Gap: The Human Skills Redefining Clinical Data Management (ACDM26 Workshop Recap)

This article has been written by Gail Kniveton, who delivered the workshop “Bridging the . . .

Regulatory Considerations DMEG reviews recent MHRA regulatory updates

The ACDM Regulatory considerations DMEG Regulatory considerations reviewed several recent . . .